Driven by strong sales in USA, the company ended the quarter on a very good note. Consolidated net sales for Q1FY15 was at Rs.3517 crore, up 24% (YoY). Its revenue from Global Generics segment grew 32% and that from Pharmaceutical Services and Active Ingredients (PSAI) segment fell 6%.  Its revenue from North America rose 51%, with four new products launched during the quarter. It had 9 product filings in the region and currently a total of 70 ANDAs are pending for approval with the USFDA of which 42 are Para IVs. Revenues from Emerging Markets showed a growth of 19%, with 18% growth in Russia and Venezuela at 25%.  India showed a growth of 15%.

The company during Q1 spent Rs.390 crore, an increase of 59% (YoY), which is 11% of revenue, up from 8.5% in previous Q1. Gross profit margin was at 59.3% v/s 52.8% (YoY). During the quarter the company launched 25 new generic products, filed 27 new product applications and 20 DMFs globally.